Čiburienė, E.; Aidietienė, S.; Ščerbickaitė, G.; Sadauskienė, E.; Sudavičienė, D.; Baltruškevičienė, E.; Brasiūnienė, B.; Drobnienė, M.; Čelutkienė, J.
Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial. Medicina 2023, 59, 2140.
https://doi.org/10.3390/medicina59122140
AMA Style
Čiburienė E, Aidietienė S, Ščerbickaitė G, Sadauskienė E, Sudavičienė D, Baltruškevičienė E, Brasiūnienė B, Drobnienė M, Čelutkienė J.
Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial. Medicina. 2023; 59(12):2140.
https://doi.org/10.3390/medicina59122140
Chicago/Turabian Style
Čiburienė, Eglė, Sigita Aidietienė, Greta Ščerbickaitė, Eglė Sadauskienė, Diana Sudavičienė, Edita Baltruškevičienė, Birutė Brasiūnienė, Monika Drobnienė, and Jelena Čelutkienė.
2023. "Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial" Medicina 59, no. 12: 2140.
https://doi.org/10.3390/medicina59122140
APA Style
Čiburienė, E., Aidietienė, S., Ščerbickaitė, G., Sadauskienė, E., Sudavičienė, D., Baltruškevičienė, E., Brasiūnienė, B., Drobnienė, M., & Čelutkienė, J.
(2023). Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial. Medicina, 59(12), 2140.
https://doi.org/10.3390/medicina59122140
